Benzinga | May 6, 2021 04:22PM EDT

Corcept Therapeutics Announces Positive Results From Its 178-Patient, Controlled, Phase 2 Trial Of Relacorilant Plus Nab-paclitaxel In Patients With Recurrent Platinum-resistant Ovarian Cancer

* Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone

* Women who received a higher dose of relacorilant given "intermittently" together with nab-paclitaxel exhibited a statistically significant improvement in their progression free survival compared to those who received nab-paclitaxel alone (median PFS: 5.6 months versus 3.8 months, hazard ratio: 0.66; p-value: 0.038)

* When a lower dose of relacorilant was given daily with nab-paclitaxel, median PFS was 1.5 months longer compared to patients who received nab-paclitaxel alone (5.3 months versus 3.8 months, hazard ratio: 0.83; p-value: NS)

* Safety and tolerability of relacorilant plus nab-paclitaxel comparable to nab-paclitaxel monotherapy

* Planning underway for Phase 3 pivotal trial